The Clozapine Handbook

Mapping Intimacies ◽

10.1017/9781108553575 ◽

2019 ◽

Author(s):

Jonathan M. Meyer ◽

Stephen M. Stahl

Keyword(s):

Adverse Effects ◽

Health Care Professionals ◽

Psychiatric Hospitalization ◽

Clinical Trial Data ◽

Trial Data ◽

Mental Illnesses ◽

Evidence Based ◽

Treatment Resistant ◽

All Cause Mortality ◽

User Friendly

Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.

Download Full-text

A Pharmacovigilance Study of Topical Acne Monotherapy with 0.1% Adapalene, and A Molecular Analytical Review of Adapalene in Evidence-Based Dermatopharmacological Treatment

International Journal of Pharmaceutical Sciences Review and Research ◽

10.47583/ijpsrr.2021.v70i02.032 ◽

2021 ◽

Vol 70 (2) ◽

Author(s):

Dr. Moumita Hazra

Keyword(s):

Adverse Effects ◽

Acne Vulgaris ◽

Global Evaluation ◽

Evidence Based ◽

Molecular Pharmacology ◽

Once Daily ◽

Significant Evidence ◽

The Face ◽

Analytical Review ◽

User Friendly

Acne vulgaris causes cosmetic impairment. User-friendly anti-acne monotherapy with adapalene has activity against the acne pathophysiology, with very minimal adverse effects. Retinoids, like adapalene, are comedolytic and anti-inflammatory. This study was conducted as a pharmacovigilance study of topical acne monotherapy with 0.1% adapalene, and a molecular analytical review of adapalene in evidence-based dermatopharmacological treatment. A prospective, open- labelled study was done, on 75 patients, with mild to moderate acne. Patients applied 0.1% adapalene topical monotherapy, once daily in the evening, over affected areas on the face, and left overnight. Efficacy was measured by percentage reduction in non-inflammatory, inflammatory and total lesion counts on 0, 15, 30, 60 and 90 days; and severity of lesions was assessed by Investigator’s Global Evaluation Scale and the occurrence of adverse effects like erythyma, dryness, scaling, burning and pruritus, were assessed by the Local Irritation Scale, among the patients receiving the monotherapy. An analytical review of the molecular pharmacology of adapalene in evidence-based dermatopharmacological treatment was thoroughly performed. The patients showed highly significant reduction in total lesion counts from baseline. No serious adverse effects were observed; and the observations were statistically non-significant. The molecular analytical review described significantly effective evidence-based dermatopharmacological response mechanisms of adapalene therapeutics. Topical 0.1% adapalene monotherapy was effective and safe, with significant evidence-based molecular dermatopharmacological efficacy.

Download Full-text

Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database

Thrombosis Research ◽

10.1016/j.thromres.2016.08.014 ◽

2016 ◽

Vol 146 ◽

pp. 43-45 ◽

Cited By ~ 3

Author(s):

Albert Trinh-Duc ◽

Agnès Lillo-Le Louët ◽

Eric Tellier ◽

Thibault Viard ◽

Grégoire Le Gal ◽

...

Keyword(s):

Clinical Trial ◽

Adverse Effects ◽

Clinical Trial Data ◽

Trial Data ◽

Spontaneous Reports ◽

Pharmacovigilance Database

Download Full-text

Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data

Oral Oncology ◽

10.1016/j.oraloncology.2019.05.013 ◽

2019 ◽

Vol 95 ◽

pp. 29-34 ◽

Cited By ~ 14

Author(s):

Adriana Blakaj ◽

Marcelo Bonomi ◽

Mauricio E. Gamez ◽

Dukagjin M. Blakaj

Keyword(s):

Clinical Trial ◽

Head And Neck Cancer ◽

Head And Neck ◽

Neck Cancer ◽

Oral Mucositis ◽

Clinical Trial Data ◽

Trial Data ◽

Evidence Based

Download Full-text

The antidepressant tale: figures signifying nothing?

Advances in Psychiatric Treatment ◽

10.1192/apt.12.5.320 ◽

2006 ◽

Vol 12 (5) ◽

pp. 320-327 ◽

Cited By ~ 13

Author(s):

David Healy

Keyword(s):

Clinical Trial ◽

Statistical Significance ◽

Healthcare Delivery ◽

Clinical Trial Data ◽

Trial Data ◽

Significance Testing ◽

Evidence Based ◽

Randomised Trials ◽

Increased Risk ◽

Based Medicine

This article reviews how data on the benefits and hazards of antidepressants have been analysed, and how conclusions drawn from these analyses conflict with the data. Randomised trials of antidepressants have for two decades consistently shown evidence of an increased risk of suicidal acts on active treatment compared with placebo, but an inappropriate application of significance testing has led to this evidence being dismissed. During the same period a minority of antidepressant trials have produced data indicative of benefits that have reached statistical significance at a 95% level. In this case significance testing appears to have led to an unrealistic impression of the likely benefits of treatment in practice. Current approaches to evidence-based medicine risk perpetuating misunderstandings of this type. Against a background of current developments in healthcare delivery, clinicians might need to reconsider how they handle and present clinical trial data.

Download Full-text

The Preschool Stuttering Screen for Health Care Professionals

Perspectives on Fluency and Fluency Disorders ◽

10.1044/ffd21.2.59 ◽

2011 ◽

Vol 21 (2) ◽

pp. 59-62

Author(s):

Joseph Donaher ◽

Christina Deery ◽

Sarah Vogel

Keyword(s):

Risk Factors ◽

Health Care ◽

Differential Diagnosis ◽

Preschool Children ◽

Health Care Professionals ◽

Healthcare Professionals ◽

Evidence Based ◽

Developmental Profile

Healthcare professionals require a thorough understanding of stuttering since they frequently play an important role in the identification and differential diagnosis of stuttering for preschool children. This paper introduces The Preschool Stuttering Screen for Healthcare Professionals (PSSHP) which highlights risk factors identified in the literature as being associated with persistent stuttering. By integrating the results of the checklist with a child’s developmental profile, healthcare professionals can make better-informed, evidence-based decisions for their patients.

Download Full-text

Moving beyond the “LDL hypothesis”

VASA ◽

10.1024/0301-1526/a000451 ◽

2015 ◽

Vol 44 (5) ◽

pp. 333-340 ◽

Cited By ~ 7

Author(s):

Christian Werner ◽

Ulrich Laufs

Keyword(s):

Ldl Cholesterol ◽

Causal Relation ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Clinical Trial Data ◽

Randomised Clinical Trial ◽

Trial Data ◽

Low Density Lipoprotein Cholesterol ◽

Genetic Studies ◽

Statin Drug

Abstract. Summary: The term “LDL hypothesis” is frequently used to describe the association of low-density lipoprotein cholesterol (LDL-cholesterol, LDL-C) and cardiovascular (CV) events. Recent data from genetic studies prove a causal relation between serum LDL-C and CV events. These data are in agreement with mechanistic molecular studies and epidemiology. New randomised clinical trial data show that LDL-C lowering with statins and a non-statin drug, ezetimibe, reduces CV events. We therefore believe that the “LDL-hypothesis” has been proven; the term appears to be outdated and should be replaced by “LDL causality”.

Download Full-text